dose escalation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
== Synthesis and structure == With the formula Zn[(S2P(OR)2]2, zinc dithiophosphate features diverse R groups. Typically, R is a branched or linear alkyl between 1-14 carbons in length. Examples include 2-butyl, pentyl, hexyl, 1,3-dimethylbutyl, heptyl, octyl, isooctyl (2-ethylhexyl), 6-methylheptyl, 1-methylpropyl, dodecylphenyl, and others. A list of examples with their CAS numbers is here. Zinc dithiophosphate are often produced in two steps. First phosphorus pentasulfide is heated with suitable alcohols (ROH) to give the dithiophosphoric acid. A wide variety of alcohols can be employed, which allows the lipophilicity of the final zinc product to be fine tuned. The resulting dithiophosphoric acid is then neutralized, e.g., with ammonia or by adding zinc oxide:
Vorster, unwilling to risk incurring the same international and domestic political fallout associated with Operation Savannah, repeatedly rejected Botha's proposals. Nevertheless, the Ministry of Defence and the SADF continued advocating air and ground attacks on PLAN's Angolan sanctuaries.
monoclonal Describing cells, proteins, or molecules descended or derived from a single clone (i.e. from the same genome or genetic lineage) or made in response to a single unique compound. Monoclonal antibodies are raised against only one antigen or can only recognize one unique epitope on the same antigen. Similarly, the cells of some tissues and neoplasms may be described as monoclonal if they are all the asexual progeny of one original parent cell. Contrast polyclonal.
According to Stéphane Quideau, the term "polyphenol" refers to compounds derived from the shikimate/phenylpropanoid and/or the polyketide pathway, featuring more than one phenolic unit and deprived of nitrogen-based functions. Ellagic acid, a molecule at the core of naturally occurring phenolic compounds of varying sizes, is itself not a polyphenol by the WBSSH definition, but is by the Quideau definition. The raspberry ellagitannin, on the other hand, with its 14 gallic acid moieties (most in ellagic acid-type components), and more than 40 phenolic hydroxyl groups, meets the criteria of both definitions of a polyphenol. Other examples of compounds that fall under both the WBSSH and Quideau definitions include the black tea theaflavin-3-gallate shown below, and the hydrolyzable tannin, tannic acid.
Sources: en.wikipedia.org
A 1968 study reported that over one-third of Puerto Rican women were not aware that tubal ligation was permanent or irreversible. Some doctors did not even request consent while other doctors threatened to not deliver the baby right before delivery unless the mother consented to sterilization after birth. If mothers were receiving government assistance, many women were threatened to have their welfare terminated. Additionally, the U.S. government and institutions worked collaboratively to incentivize sterilizations. Many doctors and hospital administrators began to encourage sterilizations due to the fact that the Joint Committee for Hospital Accreditation refused to accredit hospitals in Puerto Rico "unless a ten percent limit of sterilization (in proportion to all hospital deliveries) was agreed upon". In the 1930s, Puerto Rican women began to occupy jobs within factories. The women working in these factories felt an immense amount of pressure to undergo a sterilization to prove to employers that their pregnancy would not deter them from completing their job. This same year, approximately three sugar plantations housed birth control clinics and discriminated against women that were not sterilized as they refused employment to women who would not get the procedure. Puerto Rican women on sugar plantations were discriminated against while others were incentivized to alter their reproductive capacity to become the ideal responsible and dependable female worker.
Benzydamine (also known as Tantum Verde and branded in some countries as Maxtra Gargle, Difflam and Septabene), available as the hydrochloride salt, is a locally acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions of the mouth and throat. It falls under class of chemicals known as indazoles.
It is recommended for mothers to initiate breastfeeding within the first hour after birth. Uninterrupted skin-to-skin contact and breastfeeding can begin immediately after birth, and should continue for at least one hour after birth. This period of infant-mother interaction, known generally as kangaroo care, or the "golden hour" during the immediate postpartum period, assists in the mother–child bonding for both mother and baby, and is thought to encourage instinctual breastfeeding behavior in the infant. Newborns who are immediately placed on their mother's skin have a natural instinct to latch on to the breast and start nursing, typically within one hour of birth. Success with breastfeeding in this "golden hour" increases the likelihood of successful breastfeeding at discharge. Skin-to-skin mother-baby contact should still occur, even if the baby is born by Cesarean section. The baby is placed on the mother in the operating room or the recovery area. If the mother is unable to immediately hold the baby, a family member can provide skin-to-skin care until the mother is able.
Topiramate is used to treat epilepsy in children and adults, and it was originally used as an anticonvulsant. In children, it is indicated for the treatment of Lennox-Gastaut syndrome, a disorder that causes seizures and developmental delay. It is most frequently prescribed for the prevention of migraines, as it decreases the frequency of attacks. Topiramate is used to treat medication overuse headache and is recommended by the European Federation of Neurological Societies as one of the few medications showing effectiveness for this indication.
A feline litter usually consists of two to five kittens, but litters with one to more than ten are known. Kittens are typically born after a gestation lasting between 64 and 67 days, with an average length of 66 days. When they are born, kittens emerge in a sac called the amnion, which is bitten off and eaten by the mother cat. For the first several weeks, kittens cannot urinate or defecate without being stimulated by their mother. They also cannot regulate their body temperature for the first three weeks, so kittens born in temperatures less than 27 °C (81 °F) can die from hypothermia if their mother does not keep them warm. The mother's milk is very important for the kittens' nutrition and proper growth. This milk transfers antibodies to the kittens, which helps protect them against infectious diseases. As mentioned above, they cannot urinate, so they have a very high requirement for fluids. Kittens open their eyes about seven to ten days after birth. At first, the retina is poorly developed and vision is poor. Kittens cannot see as well as adult cats until about ten weeks after birth. Kittens develop very quickly from about two weeks of age until their seventh week. Their coordination and strength improve, and they play-fight with their littermates and begin to explore the world outside the nest or den. They learn to wash themselves and others as well as play hunting and stalking games, showing their inborn ability as predators; the kittens' mother or other adult cats help develop these innate skills by bringing live prey to the nest.
Sources: en.wikipedia.org
=== Dosing === The table below provides doses of major serotonergic psychedelics as well as the entactogen and mild psychedelic MDMA ("ecstasy") that have been determined on the basis of clinical studies. Other dosing schemes have also been reported.
In 2013, Middleton and Andy Bell founded boomf, a company that makes personalised marshmallows and greeting cards. Middleton had previously founded Nice Cakes, which specialised in personalised cakes. Bell had previously founded Mint Digital, which created StickyGram (now Sticky9), an Instagram magnet company which sold to PhotoBox. Boomf launched in November 2013 without mentioning Middleton's involvement, to allow for a low profile launch. In January 2014, Boomf announced Middleton's involvement, believing that it would be impossible to keep it secret long-term. In 2014, Boomf raised over $1m and was backed by a number of angel investors, including Nick Jenkins, founder of Moonpig, Duncan Jennings and Matt Wheeler. Boomf shipped 2 tons of marshmallows in its first year and made £100,000 ($168,000) in sales in its first three months. In 2015, the company raised funds at a valuation of £10m. Boomf made a loss of £3 million between 2015 and 2018. In July 2015, Boomf launched a nationwide search for a new marshmallow designer. The winner was Bournemouth University student Izzy Burton. Middleton's brother-in-law, hedge fund manager James Matthews paid Middleton €110,000 for 12,800 Boomf shares. In 2019, Middleton announced that the company had reached profitability with an income of £176,000 in the previous year - and an increase in sales of up to £4.4 million from £2.8 million in the previous year. The company moved into new offices in Reading with circa 20,000 square feet (1,900 m2) to warehouse space.
== Comparison == LADA differs from both type 1 and type 2 diabetes. It has a later onset and slower progression than classic type 1 diabetes and is characterized by autoimmune-mediated β-cell destruction, while also exhibiting features of type 2 diabetes due to progressive insulin deficiency over time. Genetic testing can help distinguish LADA from monogenic forms of diabetes (e.g., MODY), which lack autoimmune markers and do not share the same genetic profile.
The "open" to "closed" transformation between G and F forms and its implications on the relative motion of several key residues and the formation of water wires have been characterized in molecular dynamics and QM/MM simulations.
Public Health Emergency Preparedness initiatives are managed by the CDC via the Office of Public Health Preparedness and Response. Funds aim to support communities in preparing for public health emergencies, including pandemic influenza. Also managed by the CDC, the Strategic National Stockpile (SNS) consists of bulk quantities of medicines and supplies for use during such emergencies. Antiviral stockpiles prepare for shortages of antiviral medications in cases of public health emergencies. During the H1N1 pandemic in 2009–2010, guidelines for SNS use by local health departments was unclear, revealing gaps in antiviral planning. For example, local health departments that received antivirals from the SNS did not have transparent guidance on the use of the treatments. The gap made it difficult to create plans and policies for their use and future availabilities, causing delays in treatment.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.